First Vioxx, Then Bextra, Now Celebrex?

Siegfried, Donna Rae
March 2005
Arthritis Today;Mar/Apr2005, Vol. 19 Issue 2, p52
Deals with the withdrawal of the celocoxib drug, Celebrex from the market. Link of Celebrex with the risk of heart attack; Incidence of heart attack among people with colon polyps who take Celebrex; Other top-selling cyclooxygenase-2 inhibitors that have been recalled.


Related Articles

  • Clinical studies continue to blight COX-2 new scripts. McGuire, Stephen // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p8 

    The article reports that as new research continues to highlight the heart risks associated with COX-2 drugs as Celebrax, prescriptions for top drugs in the class have fallen dramatically. In January, the American Heart Association journal Circulation published results of another study with...

  • NEW INDICATIONS.  // Drug Topics;10/24/2005, Vol. 149 Issue 20, p32 

    This article reports on new indications granted to drugs manufactured by different manufacturers in the U.S. New indications have been granted for two Pfizer Inc.'s medications. The cyclooxygenase-2 inhibitor Celebrex (celecoxib) can now be used to relieve the signs and symptoms associated with...

  • COX-2 inhibitors associated with varying risk of MI.  // Formulary;Jan2005, Vol. 40 Issue 1, p12 

    Reports on the differential effects of COX-2 inhibitors celecoxib and rofecoxib on cardiovascular risk. Reduction of the risk of nonfatal myocardial infarction; Assessment of medication use through structured telephone interviews; Prevalence of cardiovascular risk factors among users of COX-2...

  • Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. Solomon, Scott D.; McMurray, John J.V.; Pfeffer, Marc A.; Wittes, Janet; Fowler, Robert; Finn, Peter; Anderson, William F.; Zauber, Ann; Hawk, Ernest; Bertagnolli, Monica // New England Journal of Medicine;3/17/2005, Vol. 352 Issue 11, p1071 

    Background: Selective cyclooxygenase-2 (COX-2) inhibitors have come under scrutiny because of reports suggesting an increased cardiovascular risk associated with their use. Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this...

  • Total recall. Carmichael, Helen; Odriscoll, Cath // European Chemical News;12/6/2004, Vol. 81 Issue 2127, p20 

    Discusses issues behind the withdrawal of Vioxx, a Cox-2 inhibitor arthritis drug, by Merck from the market on September 30, 2004 due to evidence that it increased the risk of heart attacks and strokes. Estimated sales of Vioxx in 2004 according to Marc Hennebert, a partner at Strategic...

  • Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Motsko, Stephen P.; Rascati, Karen L.; Busti, Anthony J.; Wilson, James P.; Barner, Jamie C.; Lawson, Kenneth A.; Worchel, Jason // Drug Safety;2006, Vol. 29 Issue 7, p621 

    BACKGROUND AND OBJECTIVE: The search for NSAIDs with less gastrointestinal toxicity led to the introduction of the selective cyclo-oxygenase-2 (COX-2) inhibitors. However, following their introduction into the market, concerns have developed regarding their safety, particularly their...

  • LBOVI-A-4. Schneeweiss, S.; Solomon, D. H.; Wang, P. S.; Brookhart, A. // Clinical Pharmacology & Therapeutics;Feb2006, Vol. 79 Issue 2, pP83 

    Background: A direct comparison of the gastrointestinal (GI) and cardiac safety of NSAIDs in elderly patients is not possible based on randomized trials since different trials employed non-overlapping patient populations and comparison exposures. We sought to estimate the risk reduction of GI...

  • NSAIDs after a MI could be fatal.  // Reactions Weekly;12/3/2005, Issue 1080, p5 

    The article discusses research being done on the association of COX-2 inhibitors and other nonsteroidal anti-inflammatory agents (NSAID) with the risk of death after a myocardial infarction (MI). It references a study by G. H. Gislason et al published in the October 25, 2005 issue of the...

  • Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction. Kimmel, Stephen E.; Berlin, Jesse A.; Reilly, Muredach; Jaskowiak, Jane; Kishel, Lori; Chittams, Jesse; Strom, Brian L. // Annals of Internal Medicine;2/1/2005, Vol. 142 Issue 3, p157 

    Background: Studies have postulated that cyclooxygenase-2 (COX-2) selective inhibitors affect cardiovascular risk through various mechanisms. Some of these mechanisms could increase risk (for example, inhibition of prostacyclin production), and some could decrease risk (for example, inhibition...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics